Floatz logo

ENCENICLINE

Impaired Cognition

FORUM Pharmaceuticals IncSmall moleculePhase 3Dormant
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
52/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Impaired Cognition cohort.

Asset / SponsorPhaseRating
Mirabegron
HealthPartners Institute
Phase 4BB
TENOFOVIR DISOPROXIL FUMARATE
Azienda Ospedaliera San Gerardo di Monza
Phase 4BB
(±)-FTC
Azienda Ospedaliera San Gerardo di Monza
Phase 4BB
Sra-333
Central South University
Phase 4BB
Carboplatin
University Hospital, Angers
D
Toripalimab
University Hospital, Angers
D

Same molecule, other indications

ENCENICLINE is also rated in:

central nervous system disorderDormant
BB
Indicative ·
64 / 100
View asset →
schizophreniaDormant
B
Indicative ·
62 / 100
View asset →
cognitive disorderDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →